S17 Ep72: HIF-2 Targeting Is Set to Transform Kidney Cancer Management: With Chandler Park, MD; and Katy Beckermann, MD
In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Katy Beckermann, MD, to discuss kidney cancer highlights from the 2026 Genitourinary Cancers Symposium. Dr Beckermann is director of Genitourinary Cancer Research at Tennessee Oncology in Franklin.
Their conversation focused on the clinical evolution of HIF-2 targeting, specifically the integration of belzutifan (Welireg) into earlier lines of therapy and novel combinations. Drs. Park and Beckerman examined the phase 3 LITESPARK-022 trial…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.